Adaptimmune Therapeutics plc American Depositary Shares (ADAP) Revenue (2015 - 2025)
Adaptimmune Therapeutics plc American Depositary Shares (ADAP) revenue from Jun 30, 2015 to Jun 30, 2025. The TTM Adaptimmune Therapeutics plc American Depositary Shares (ADAP) revenue is $62M. You can adjust inflation or export chart.
Annual Revenue
Quarterly Revenue
Adaptimmune Therapeutics plc American Depositary Shares (ADAP) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -55.20% |
| 3 Years TTM | +69.37% |
| 5 Years TTM | +55.41% |
| 10 Years TTM | +36.49% |
| All Time TTM | +25.29% |
Annual Revenue change of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)
| Year | Revenue | Change |
|---|---|---|
| 2025 | $21M | -88.22% |
| 2024 | $178M | +195.34% |
| 2023 | $60M | +122.03% |
| 2022 | $27M | +275.00% |
| 2021 | $7.24M | +15.47% |
| 2020 | $6.27M | +61.18% |
| 2019 | $3.89M | -93.76% |
| 2018 | $62M | +64.82% |
| 2017 | $38M | +166.41% |
| 2016 | $14M | +83.70% |
| 2015 | $7.73M | N/A |
Comparison Adaptimmune Therapeutics plc American Depositary Shares (ADAP) five years revenue CAGR with competitors
Adaptimmune Therapeutics plc American Depositary Shares (ADAP) five years revenue CAGR is 55.42%.